MCRB, US81750R2013

Seres Therapeutics sets November 4 results date for MCRB stock

Published on 10/20/2026 at 20:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq market value was USD 23.9 million on October 20, 2026. MCRB stock costs EUR 2.17 on October 20, 2026 at 7:53 p.m. CEST.

Reporting date and operating figures

Seres Therapeutics is estimated to report third-quarter 2026 results on November 4, 2026.
MarketBeat lists consensus revenue of USD 6.35 million and consensus earnings of minus USD 1.0050 per share for the quarter.
Seres Therapeutics stock costs EUR 2.17 at Lang & Schwarz on October 20, 2026 at 7:53 p.m. CEST.

MCRB, US81750R2013, Illustration mit AI erstellt.

Seres Therapeutics is estimated to report third-quarter 2026 results on November 4, 2026, before the market opens, according to MarketBeat. The company is developing live biotherapeutics for microbiome-related diseases. Its stock was at EUR 2.17 at Lang & Schwarz on October 20, 2026 at 7:53 p.m. CEST.

November 4 carries the next test

The upcoming report matters because MarketBeat lists consensus revenue of USD 6.35 million and consensus earnings of minus USD 1.0050 per share for the third quarter of 2026. The same source identifies the announcement as an estimate and places the conference call at 8:30 a.m. ET.

Seres last reported second-quarter 2026 results on August 5, 2026, when revenue was USD 736,000 and diluted earnings per share were USD 0.47, according to MarketBeat. That comparison gives the November estimate a clear operating benchmark, although the reporting date itself remains labeled as estimated.

Stock position remains wide

On October 20, 2026, Nasdaq quote data put MCRB at USD 2.40 at 1:58 p.m. EDT, with a 52-week range of USD 2.38 to USD 29.98. The market capitalization was USD 23.9 million, while the latest euro quotation stood at EUR 2.17 at Lang & Schwarz at 7:53 p.m. CEST.

The distance between the Nasdaq low and high underlines the stock's broad trading history. Seres Therapeutics operates in biotechnology and has 66 full-time employees, with Richard N. Kender as chief executive officer.

Pipeline work meets funding pressure

Seres is advancing SER-155 and other live biotherapeutic candidates, while recent company materials describe research focused on infections and immune-related complications. A Simply Wall St analysis published October 6, 2026, put the analyst consensus target at USD 17.00 and cited cash of USD 45.8 million at December 31, 2025, but those figures are historical or analytical context rather than a new company announcement.

Stock and reporting date

The next scheduled corporate milestone is the estimated November 4, 2026, third-quarter report. Until then, the market picture combines a USD 2.40 Nasdaq quote, a USD 23.9 million market capitalization and a EUR 2.17 Lang & Schwarz quotation.

The further course of trading is shown by the continuously updated real-time quote of Seres Therapeutics stock.